ODS Acting Director
This article was originally published in The Tan Sheet
Executive Summary
Ralph Lillie has been named acting director of the Office of Drug Safety, the Center for Drug Evaluation & Research announced Jan. 23; he will remain in place as the center searches for a permanent director, according to CDER Acting Director Steve Galson. Lillie has led emergency preparedness efforts in the Office of Executive Operations, and was deputy director of the Office of Postmarketing Drug Risk Assessment from 1997 to 1999...
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.